Steven M. Paul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Steven M. Paul has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Christine Miaskowski
School of Nursing, University of California, San Francisco
22 shared publications - Bruce A. Cooper
School of Nursing, University of California, San Francisco, CA, USA
17 shared publications - Marilyn J. Hammer
Dana‐Farber Cancer Institute Boston Massachusetts USA
16 shared publications - Jon D. Levine
School of Medicine, University of California, San Francisco, USA
14 shared publications - Yvette P. Conley
University of Pittsburgh
13 shared publications - Kate R. Oppegaard
Department of Nursing Professional Services & National Center for Rehabilitative Auditory Research VA Portland Health Care System Portland Oregon USA
11 shared publications
Latest Publications
- 2 June 2026
- Published by Wolters Kluwer Health in Nursing Research
- Vol. 75 (6) , 489-494
Study Protocol to Characterize Symptom Experience During Immune Checkpoint Inhibitor Therapy for Cutaneous Melanoma
Background: Treatment of patients with stages IIB to IV cutaneous melanoma with immune checkpoint inhibitors (ICIs) has resulted in dramatic improvements in mortality rates. With this rapid shift in treatment, significant gaps in knowledge exist regarding the effect of ICIs on patients’ symptom experiences. An in-depth characterization of interindividual differences in symptom experiences and the identification of risk factors associated with a worse symptom experience will fill this gap and assist with early detection of ICI toxicity, guide symptom management, inform treatment decision-making, and refine ICI-symptom instrument development. Objectives: Across four ICI cycles for patients with stage IIB to IV cutaneous melanoma, study objectives are to describe the occurrence, severity, and distress of 53 symptoms; identify symptom clusters based on symptom dimensions (i.e., occurrence, severity, distress); evaluate the stability and consistency of symptom clusters across symptom dimensions and time; identify subgroups of patients with distinct symptom profiles; and evaluate for differences among the symptom profiles in demographic and clinical characteristics and levels of cancer-related stress, financial toxicity, and quality of life (QOL). Methods: This longitudinal, descriptive study is recruiting 300 adults with stage IIB to IV cutaneous melanoma who will start an ICI regimen and follow them for four cycles. Participants complete demographic, stress, financial toxicity, and QOL questionnaires before their first and fourth ICI cycles. Before each cycle, participants report the occurrence, severity, and distress of 53 symptoms using a modified version of the Memorial Symptom Assessment Scale. Symptom clusters will be identified using exploratory factor analysis. Subgroups of participants with distinct symptom profiles will be identified across the ICI cycles using latent class and latent profile analysis. Differences among the latent classes will be evaluated using parametric and nonparametric tests. Results: Participant recruitment began in October 2025 and will be completed in June 2027. Discussion: This study will fill important knowledge gaps about interindividual differences in risk factors for a worse symptom experience in adults with cutaneous melanoma receiving ICIs. This knowledge is critical to inform clinical assessment and monitoring of high-risk patients and to inform future biomarker research and intervention development.
- 2 June 2026
- Published by Wolters Kluwer Health in Nursing Research
- Vol. 75 (6) , 489-494
Study Protocol to Characterize Symptom Experience During Immune Checkpoint Inhibitor Therapy for Cutaneous Melanoma
Background: Treatment of patients with stages IIB to IV cutaneous melanoma with immune checkpoint inhibitors (ICIs) has resulted in dramatic improvements in mortality rates. With this rapid shift in treatment, significant gaps in knowledge exist regarding the effect of ICIs on patients’ symptom experiences. An in-depth characterization of interindividual differences in symptom experiences and the identification of risk factors associated with a worse symptom experience will fill this gap and assist with early detection of ICI toxicity, guide symptom management, inform treatment decision-making, and refine ICI-symptom instrument development. Objectives: Across four ICI cycles for patients with stage IIB to IV cutaneous melanoma, study objectives are to describe the occurrence, severity, and distress of 53 symptoms; identify symptom clusters based on symptom dimensions (i.e., occurrence, severity, distress); evaluate the stability and consistency of symptom clusters across symptom dimensions and time; identify subgroups of patients with distinct symptom profiles; and evaluate for differences among the symptom profiles in demographic and clinical characteristics and levels of cancer-related stress, financial toxicity, and quality of life (QOL). Methods: This longitudinal, descriptive study is recruiting 300 adults with stage IIB to IV cutaneous melanoma who will start an ICI regimen and follow them for four cycles. Participants complete demographic, stress, financial toxicity, and QOL questionnaires before their first and fourth ICI cycles. Before each cycle, participants report the occurrence, severity, and distress of 53 symptoms using a modified version of the Memorial Symptom Assessment Scale. Symptom clusters will be identified using exploratory factor analysis. Subgroups of participants with distinct symptom profiles will be identified across the ICI cycles using latent class and latent profile analysis. Differences among the latent classes will be evaluated using parametric and nonparametric tests. Results: Participant recruitment began in October 2025 and will be completed in June 2027. Discussion: This study will fill important knowledge gaps about interindividual differences in risk factors for a worse symptom experience in adults with cutaneous melanoma receiving ICIs. This knowledge is critical to inform clinical assessment and monitoring of high-risk patients and to inform future biomarker research and intervention development.
- Open Access
- 1 January 2025
- Published by Wiley in European Journal of Cancer Care
- Vol. 2025 (1)
Lower Functional Status, Higher Comorbidity Burden, and Higher Levels of Stress Are Associated With Worse Joint Evening Fatigue and Depressive Symptom Profiles in Outpatients Receiving Chemotherapy
Significance: Evening fatigue and depressive symptoms are associated with several negative outcomes for patients with cancer. However, the contribution of BOTH fatigue and depressive symptoms to patient outcomes remains unknown. This study identified subgroups of patients with distinct joint evening fatigue AND depressive symptom profiles and evaluated for differences in demographic and clinical characteristics, levels of stress (i.e., global, cancer‐specific, and cumulative life) and resilience, and the severity of common symptoms. Methods: Outpatients ( n = 1334) completed the Lee Fatigue Scale and Center for Epidemiological Studies‐Depression scale six times over two cycles of chemotherapy. Demographic and clinical characteristics, stress and resilience, and other common symptoms were assessed at enrollment. Joint evening fatigue and depressive symptom profiles were identified using latent profile analysis. Profile differences were assessed using parametric and nonparametric tests. Results: Five profiles were identified (i.e., Low Evening Fatigue and Low Depression [Both Low: 20.0%], Moderate Evening Fatigue and Low Depression [Moderate Fatigue and Low Depression: 39.3%], Increasing and Decreasing Evening Fatigue and Depression [Both Increasing–Decreasing: 5.3%], Moderate Evening Fatigue and Moderate Depression [Both Moderate: 27.6%], High Evening Fatigue and High Depression [Both High: 7.8%]). Compared to the Both Low and Moderate Fatigue and Low Depression classes, the Both Moderate and Both High classes were less likely to be married, more likely to report depression, had a lower functional status, and had worse comorbidity profile. Both Moderate and Both High classes had higher levels of global, cancer‐specific, and cumulative life stress and lower resilience. Conclusions: Multiple risk factors for higher levels of evening fatigue AND depressive symptoms during chemotherapy were identified, including lower functional status, higher comorbidity burden, lower levels of resilience, and higher global, cancer‐specific, and cumulative life stress. These risk factors may be used to identify patients at greatest risk for poorer outcomes and to prescribe interventions to decrease these symptoms.
- 1 January 2025
- Published by Wiley in European Journal of Cancer Care
- Vol. 2025 (1)
Open AccessLower Functional Status, Higher Comorbidity Burden, and Higher Levels of Stress Are Associated With Worse Joint Evening Fatigue and Depressive Symptom Profiles in Outpatients Receiving Chemotherapy
Significance: Evening fatigue and depressive symptoms are associated with several negative outcomes for patients with cancer. However, the contribution of BOTH fatigue and depressive symptoms to patient outcomes remains unknown. This study identified subgroups of patients with distinct joint evening fatigue AND depressive symptom profiles and evaluated for differences in demographic and clinical characteristics, levels of stress (i.e., global, cancer‐specific, and cumulative life) and resilience, and the severity of common symptoms. Methods: Outpatients ( n = 1334) completed the Lee Fatigue Scale and Center for Epidemiological Studies‐Depression scale six times over two cycles of chemotherapy. Demographic and clinical characteristics, stress and resilience, and other common symptoms were assessed at enrollment. Joint evening fatigue and depressive symptom profiles were identified using latent profile analysis. Profile differences were assessed using parametric and nonparametric tests. Results: Five profiles were identified (i.e., Low Evening Fatigue and Low Depression [Both Low: 20.0%], Moderate Evening Fatigue and Low Depression [Moderate Fatigue and Low Depression: 39.3%], Increasing and Decreasing Evening Fatigue and Depression [Both Increasing–Decreasing: 5.3%], Moderate Evening Fatigue and Moderate Depression [Both Moderate: 27.6%], High Evening Fatigue and High Depression [Both High: 7.8%]). Compared to the Both Low and Moderate Fatigue and Low Depression classes, the Both Moderate and Both High classes were less likely to be married, more likely to report depression, had a lower functional status, and had worse comorbidity profile. Both Moderate and Both High classes had higher levels of global, cancer‐specific, and cumulative life stress and lower resilience. Conclusions: Multiple risk factors for higher levels of evening fatigue AND depressive symptoms during chemotherapy were identified, including lower functional status, higher comorbidity burden, lower levels of resilience, and higher global, cancer‐specific, and cumulative life stress. These risk factors may be used to identify patients at greatest risk for poorer outcomes and to prescribe interventions to decrease these symptoms.
- Open Access
- 26 September 2024
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (2) , 275-286
Self-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways
Background: Cancer-related cognitive impairment (CRCI) is reported by 45% of patients with cancer. Significant gaps in knowledge remain regarding the mechanisms that underlie CRCI. Objectives: Using a data-driven approach, the study purpose was to evaluate for perturbed pathways associated with membership in the High versus the Low CRCI profiles. Methods: Patients completed the Attentional Function Index six times over two cycles of chemotherapy. Using findings from a previous latent profile analysis, subgroups of patients with high versus low levels of CRCI were evaluated (i.e., High versus Low CRCI profiles). Gene expression was quantified using either ribonucleic (RNA)-sequencing or microarray analyses and pathway impact analyses were performed. Signaling pathways were defined using the Kyoto Encyclopedia of Genes and Genomes database. Results: A total of 508 patients had data available for analysis. Of the 261 patients in the RNA-sequencing sample, 48.7% were in the High class and 51.3% were in the Low class. Of the 247 patients the microarray sample, 46.6% were in the High class and 53.4% were in the Low class. Pathway impact analyses identified seven perturbed pathways related to neurotransmission (i.e., glutamatergic synapse, GABAergic synapse, dopaminergic synapse, serotonergic synapse, long-term depression, cholinergic synapse, retrograde endocannabinoid signaling). Conclusions: This study is the first to describe associations between self-reported CRCI in patients receiving chemotherapy for breast, gastrointestinal, gynecological, or lung cancer and seven neurotransmission pathways. These findings provide new insights into potential targets for mechanistically based interventions.
- 26 September 2024
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 132 (2) , 275-286
Open AccessSelf-reported cancer-related cognitive impairment is associated with perturbed neurotransmission pathways
Background: Cancer-related cognitive impairment (CRCI) is reported by 45% of patients with cancer. Significant gaps in knowledge remain regarding the mechanisms that underlie CRCI. Objectives: Using a data-driven approach, the study purpose was to evaluate for perturbed pathways associated with membership in the High versus the Low CRCI profiles. Methods: Patients completed the Attentional Function Index six times over two cycles of chemotherapy. Using findings from a previous latent profile analysis, subgroups of patients with high versus low levels of CRCI were evaluated (i.e., High versus Low CRCI profiles). Gene expression was quantified using either ribonucleic (RNA)-sequencing or microarray analyses and pathway impact analyses were performed. Signaling pathways were defined using the Kyoto Encyclopedia of Genes and Genomes database. Results: A total of 508 patients had data available for analysis. Of the 261 patients in the RNA-sequencing sample, 48.7% were in the High class and 51.3% were in the Low class. Of the 247 patients the microarray sample, 46.6% were in the High class and 53.4% were in the Low class. Pathway impact analyses identified seven perturbed pathways related to neurotransmission (i.e., glutamatergic synapse, GABAergic synapse, dopaminergic synapse, serotonergic synapse, long-term depression, cholinergic synapse, retrograde endocannabinoid signaling). Conclusions: This study is the first to describe associations between self-reported CRCI in patients receiving chemotherapy for breast, gastrointestinal, gynecological, or lung cancer and seven neurotransmission pathways. These findings provide new insights into potential targets for mechanistically based interventions.
Neurodegenerative disease pathways are perturbed in patients with cancer who self‐report cognitive changes and anxiety: A pathway impact analysis
Background: Cancer‐related cognitive impairment (CRCI) and anxiety co‐occur in patients with cancer. Little is known about mechanisms for the co‐occurrence of these two symptoms. The purposes of this secondary analysis were to evaluate for perturbed pathways associated with the co‐occurrence of self‐reported CRCI and anxiety in patients with low versus high levels of these two symptoms and to identify potential mechanisms for the co‐occurrence of CRCI and anxiety using biological processes common across any perturbed neurodegenerative disease pathways.Methods: Patients completed the Attentional Function Index and the Spielberger State‐Trait Anxiety Inventory six times over two cycles of chemotherapy. Based on findings from a previous latent profile analysis, patients were grouped into none versus both high levels of these symptoms. Gene expression was quantified, and pathway impact analyses were performed. Signaling pathways for evaluation were defined with the Kyoto Encyclopedia of Genes and Genomes database.Results: A total of 451 patients had data available for analysis. Approximately 85.0% of patients were in the none class and 15.0% were in the both high class. Pathway impact analyses identified five perturbed pathways related to neurodegenerative diseases (i.e., amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, prion disease, and pathways of neurodegeneration–multiple diseases). Apoptosis, mitochondrial dysfunction, oxidative stress, and endoplasmic reticulum stress were common biological processes across these pathways.Conclusions: This study is the first to describe perturbations in neurodegenerative disease pathways associated with CRCI and anxiety in patients receiving chemotherapy. These findings provide new insights into potential targets for the development of mechanistically based interventions.
Neurodegenerative disease pathways are perturbed in patients with cancer who self‐report cognitive changes and anxiety: A pathway impact analysis
Background: Cancer‐related cognitive impairment (CRCI) and anxiety co‐occur in patients with cancer. Little is known about mechanisms for the co‐occurrence of these two symptoms. The purposes of this secondary analysis were to evaluate for perturbed pathways associated with the co‐occurrence of self‐reported CRCI and anxiety in patients with low versus high levels of these two symptoms and to identify potential mechanisms for the co‐occurrence of CRCI and anxiety using biological processes common across any perturbed neurodegenerative disease pathways.Methods: Patients completed the Attentional Function Index and the Spielberger State‐Trait Anxiety Inventory six times over two cycles of chemotherapy. Based on findings from a previous latent profile analysis, patients were grouped into none versus both high levels of these symptoms. Gene expression was quantified, and pathway impact analyses were performed. Signaling pathways for evaluation were defined with the Kyoto Encyclopedia of Genes and Genomes database.Results: A total of 451 patients had data available for analysis. Approximately 85.0% of patients were in the none class and 15.0% were in the both high class. Pathway impact analyses identified five perturbed pathways related to neurodegenerative diseases (i.e., amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, prion disease, and pathways of neurodegeneration–multiple diseases). Apoptosis, mitochondrial dysfunction, oxidative stress, and endoplasmic reticulum stress were common biological processes across these pathways.Conclusions: This study is the first to describe perturbations in neurodegenerative disease pathways associated with CRCI and anxiety in patients receiving chemotherapy. These findings provide new insights into potential targets for the development of mechanistically based interventions.
- Open Access
- 1 February 2024
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 67 (5) , 375-383.e3
Identification Of A Higher Risk Lymphedema Phenotype And Associations With Cytokine Gene Polymorphisms
- 1 February 2024
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 67 (5) , 375-383.e3
Open AccessIdentification Of A Higher Risk Lymphedema Phenotype And Associations With Cytokine Gene Polymorphisms
- 3 June 2023
- Published by Elsevier in Sleep Medicine
- Vol. 108, 124-136
Sleep disturbance and decrements in morning energy contribute to a higher symptom burden in oncology patients
- 3 June 2023
- Published by Elsevier in Sleep Medicine
- Vol. 108, 124-136
Sleep disturbance and decrements in morning energy contribute to a higher symptom burden in oncology patients
- 24 April 2023
- Published by Wolters Kluwer Health in Nursing Research
- Vol. 72 (4) , 272-280
An Evaluation of the Multifactorial Model of Cancer-Related Cognitive Impairment
Background: Up to 45% of patients report cancer-related cognitive impairment (CRCI). A variety of characteristics are associated with the occurrence and/or severity of CRCI. However, an important gap in knowledge of risk factors for CRCI is the relative contribution of each factor. The multifactorial model of cancer-related cognitive impairment (MMCRCI) is a conceptual model of CRCI that can be used to evaluate the strength of relationships between various factors and CRCI. Objectives: The purpose of this study was to use structural regression methods to evaluate the MMCRCI using data from a large sample of outpatients receiving chemotherapy (n = 1,343). Specifically, the relationships between self-reported CRCI and four MMCRCI concepts (i.e., social determinants of health, patient-specific factors, treatment factors, and co-occurring symptoms) were examined. The goals were to determine how well the four concepts predicted CRCI and determine the relative contribution of each concept to deficits in perceived cognitive function. Methods: This study is part of a larger, longitudinal study that evaluated the symptom experience of oncology outpatients receiving chemotherapy. Adult patients were diagnosed with breast, gastrointestinal, gynecological, or lung cancer; had received chemotherapy within the preceding 4 weeks; were scheduled to receive at least two additional cycles of chemotherapy; were able to read, write, and understand English; and gave written informed consent. Self-reported CRCI was assessed using the attentional function index. Available study data were used to define the latent variables. Results: On average, patients were 57 years of age, college educated, and with a mean Karnofsky Performance Status score of 80. Of the four concepts evaluated, whereas co-occurring symptoms explained the largest amount of variance in CRCI, treatment factors explained the smallest amount of variance. A simultaneous structural regression model that estimated the joint effect of the four exogenous latent variables on the CRCI latent variable was not significant. Discussion: These findings suggest that testing individual components of the MMCRCI may provide useful information on the relationships among various risk factors, as well as refinements of the model. In terms of risk factors for CRCI, co-occurring symptoms may be more significant than treatment factors, patient-specific factors, and/or social determinants of health in patients receiving chemotherapy.
- 24 April 2023
- Published by Wolters Kluwer Health in Nursing Research
- Vol. 72 (4) , 272-280
An Evaluation of the Multifactorial Model of Cancer-Related Cognitive Impairment
Background: Up to 45% of patients report cancer-related cognitive impairment (CRCI). A variety of characteristics are associated with the occurrence and/or severity of CRCI. However, an important gap in knowledge of risk factors for CRCI is the relative contribution of each factor. The multifactorial model of cancer-related cognitive impairment (MMCRCI) is a conceptual model of CRCI that can be used to evaluate the strength of relationships between various factors and CRCI. Objectives: The purpose of this study was to use structural regression methods to evaluate the MMCRCI using data from a large sample of outpatients receiving chemotherapy (n = 1,343). Specifically, the relationships between self-reported CRCI and four MMCRCI concepts (i.e., social determinants of health, patient-specific factors, treatment factors, and co-occurring symptoms) were examined. The goals were to determine how well the four concepts predicted CRCI and determine the relative contribution of each concept to deficits in perceived cognitive function. Methods: This study is part of a larger, longitudinal study that evaluated the symptom experience of oncology outpatients receiving chemotherapy. Adult patients were diagnosed with breast, gastrointestinal, gynecological, or lung cancer; had received chemotherapy within the preceding 4 weeks; were scheduled to receive at least two additional cycles of chemotherapy; were able to read, write, and understand English; and gave written informed consent. Self-reported CRCI was assessed using the attentional function index. Available study data were used to define the latent variables. Results: On average, patients were 57 years of age, college educated, and with a mean Karnofsky Performance Status score of 80. Of the four concepts evaluated, whereas co-occurring symptoms explained the largest amount of variance in CRCI, treatment factors explained the smallest amount of variance. A simultaneous structural regression model that estimated the joint effect of the four exogenous latent variables on the CRCI latent variable was not significant. Discussion: These findings suggest that testing individual components of the MMCRCI may provide useful information on the relationships among various risk factors, as well as refinements of the model. In terms of risk factors for CRCI, co-occurring symptoms may be more significant than treatment factors, patient-specific factors, and/or social determinants of health in patients receiving chemotherapy.
- 18 April 2023
- Published by Wolters Kluwer Health in Nursing Research
- Vol. 72 (4) , 259-271
Distinct Profiles of Morning and Evening Fatigue Co-Occurrence in Patients During Chemotherapy
Background: Morning and evening fatigue are distinct and distressing symptoms experienced during chemotherapy that demonstrate a large amount of interindividual variability. Objectives: The objectives of this study were to identify subgroups of patients with distinct morning and evening fatigue co-occurrence profiles and evaluate for differences among these subgroups in demographic, clinical, and symptom characteristics and quality of life. Methods: Oncology patients (n = 1,334) completed the Lee Fatigue Scale to self-report morning and evening fatigue, six times over two cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct morning and evening physical fatigue profiles. Results: Four distinct morning and evening fatigue profiles were identified (i.e., Both Low, Low Morning + Moderate Evening, Both Moderate, and Both High). Compared to the Both Low profile, the Both High profile was significantly younger, less likely to be married or partnered, more likely to live alone, had a higher comorbidity burden, and lower functional status. The Both High profile had higher levels of anxiety, depressive symptoms, sleep disturbance, and pain and lower levels of quality of life. Discussion: The variability in the morning and evening severity scores among the four profiles supports the hypothesis that morning and evening fatigue are distinct but related symptoms. Clinically meaningful levels of both morning and evening fatigue were reported by 50.4% of our sample, which suggests that the co-occurrence of these two symptoms is relatively common. Patients in Both Moderate and Both High profiles experienced an extremely high symptom burden that warrants ongoing assessments and aggressive symptom management interventions.
- 18 April 2023
- Published by Wolters Kluwer Health in Nursing Research
- Vol. 72 (4) , 259-271
Distinct Profiles of Morning and Evening Fatigue Co-Occurrence in Patients During Chemotherapy
Background: Morning and evening fatigue are distinct and distressing symptoms experienced during chemotherapy that demonstrate a large amount of interindividual variability. Objectives: The objectives of this study were to identify subgroups of patients with distinct morning and evening fatigue co-occurrence profiles and evaluate for differences among these subgroups in demographic, clinical, and symptom characteristics and quality of life. Methods: Oncology patients (n = 1,334) completed the Lee Fatigue Scale to self-report morning and evening fatigue, six times over two cycles of chemotherapy. Latent profile analysis was used to identify subgroups of patients with distinct morning and evening physical fatigue profiles. Results: Four distinct morning and evening fatigue profiles were identified (i.e., Both Low, Low Morning + Moderate Evening, Both Moderate, and Both High). Compared to the Both Low profile, the Both High profile was significantly younger, less likely to be married or partnered, more likely to live alone, had a higher comorbidity burden, and lower functional status. The Both High profile had higher levels of anxiety, depressive symptoms, sleep disturbance, and pain and lower levels of quality of life. Discussion: The variability in the morning and evening severity scores among the four profiles supports the hypothesis that morning and evening fatigue are distinct but related symptoms. Clinically meaningful levels of both morning and evening fatigue were reported by 50.4% of our sample, which suggests that the co-occurrence of these two symptoms is relatively common. Patients in Both Moderate and Both High profiles experienced an extremely high symptom burden that warrants ongoing assessments and aggressive symptom management interventions.
- 22 November 2022
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 65 (3) , 203-215
Higher Stress in Oncology Patients is Associated With Cognitive and Evening Physical Fatigue Severity
- 22 November 2022
- Published by Elsevier in Journal of Pain and Symptom Management
- Vol. 65 (3) , 203-215
Higher Stress in Oncology Patients is Associated With Cognitive and Evening Physical Fatigue Severity
- Open Access
- 21 November 2022
- Published by Elsevier in Sleep Medicine
- Vol. 101, 305-315
Sleep disturbance is associated with perturbations in immune-inflammatory pathways in oncology outpatients undergoing chemotherapy
- 21 November 2022
- Published by Elsevier in Sleep Medicine
- Vol. 101, 305-315
Open AccessSleep disturbance is associated with perturbations in immune-inflammatory pathways in oncology outpatients undergoing chemotherapy